What is NuSmile?
Founded in 1991 in Houston, Texas, by Diane Johnson Krueger, NuSmile has evolved into the worldwide leader in pediatric esthetic restorative dentistry. The company is recognized for its pioneering role in the development of esthetic pediatric crowns, having facilitated over 4 million restorations since its inception. Its current product portfolio is anchored by the NuSmile ZR Zirconia crown system, which integrates innovative features such as Try-In crowns to mitigate contamination risks, and the BioCem BioActive Cement, known for superior bond strength. Beyond its hardware, NuSmile maintains a robust ecosystem of research and education, providing critical support to major professional bodies including the American Academy of Pediatric Dentistry and the International Association of Pediatric Dentistry. This dedication to clinical excellence and practitioner support positions the company as an essential partner for dental professionals serving pediatric populations globally.
How much funding has NuSmile raised?
NuSmile has raised a total of $992K across 2 funding rounds:
Debt
$350K
Debt
$642K
Debt (2020): $350K with participation from PPP
Debt (2021): $642K led by PPP
Key Investors in NuSmile
PPP
Public-Private Partnership
What's next for NuSmile?
Looking ahead, the infusion of capital is expected to accelerate NuSmile's research and development pipeline, particularly in the realm of bioactive materials and advanced pulp therapy solutions like NeoMTA. By leveraging this recent financing, the company is well-positioned to enhance its manufacturing efficiencies and deepen its engagement with international dental associations. As the demand for high-quality, esthetic pediatric dental solutions continues to rise, NuSmile's strategic focus will likely remain on maintaining its technological edge while expanding its distribution networks to ensure that its restorative systems remain the gold standard for pediatric dentists worldwide. The company's trajectory suggests a continued emphasis on evidence-based innovation and long-term clinical outcomes.
See full NuSmile company page
